Is Deciphera Pharmaceuticals, Inc. overvalued or undervalued?

As of 15 October 2023, Deciphera Pharmaceuticals, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 12.5, a price-to-sales (P/S) ratio of 3.0, and a return on equity (ROE) of 15%.
In comparison to its peers, Blueprint Medicines Corporation has a P/E ratio of 18.0, while Mirati Therapeutics, Inc. stands at a P/S ratio of 5.0. These comparisons indicate that Deciphera is trading at a discount relative to its industry counterparts. Additionally, recent stock performance shows that Deciphera has outperformed the Sensex, reinforcing the notion of its undervaluation.